Figure 1.
Outcomes in patients who underwent mobilized blood–derived related haploidentical allogeneic HCT. (A) Frequency plot of CD34+ stem cell dose per recipient weight (kg). There is a strong bias toward the use of ∼5 × 106 CD34+ cells per kg. (B) Cumulative incidence of primary neutrophil engraftment based on the CD34+ cell dose per kg. (C) Overall survival. (D) Cumulative incidence of grade 3 or 4 acute GVHD. (E) Cumulative incidence of moderate-to-severe chronic GVHD.

Outcomes in patients who underwent mobilized blood–derived related haploidentical allogeneic HCT. (A) Frequency plot of CD34+ stem cell dose per recipient weight (kg). There is a strong bias toward the use of ∼5 × 106 CD34+ cells per kg. (B) Cumulative incidence of primary neutrophil engraftment based on the CD34+ cell dose per kg. (C) Overall survival. (D) Cumulative incidence of grade 3 or 4 acute GVHD. (E) Cumulative incidence of moderate-to-severe chronic GVHD.

Close Modal

or Create an Account

Close Modal
Close Modal